This morning at the European Society of Cardiology (ESC) Congress 2024, Eli Lilly and Co announced the most recent trial results for retatrutide related to cardiovascular risk factors. Eli Lilly ...
"Dyslipidemia" refers to an abnormality within the lipid profile, encompassing a variety of disorders relating to elevations in total cholesterol, LDL, or TG, or conversely, lower levels of HDL.
In conclusion, retatrutide seems to improve the cardiovascular risk profile and lipid profile of patients in a dose-dependent manner. This drug has the potential to one day become a blockbuster in ...